Mobidiag Signs New International Agreements for Distribution of its Amplidiag® and Novodiag® Diagnostic Solutions
Mobidiag Ltd., a molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has signed new exclusive agreements with international partners for the distribution of its Amplidiag® and Novodiag® products in Europe and the Middle East.
Mobidiag has signed exclusive agreements for the distribution of Amplidiag® and Novodiag® with ALAB Ltd. for Poland and Ukraine, BIOgenetiX for Romania and Theranostica Ltd. for Israel.
Tuomas Tenkanen, CEO of Mobidiag, said “We are extremely pleased to have further expanded our commercial footprint into additional international territories. Our highly versatile and complementary Amplidiag® and Novodiag® diagnostic solutions continue to gain traction internationally. We are in ongoing discussions with several distribution partners in a range of international markets as customers look for fast, accurate and affordable diagnostic solutions to a wide range of infectious diseases.”
Gilda Cristea, Imports Manager of BIOgenetiX, comments “ It is a great opportunity for BIOgenetiX to collaborate with Mobidiag in Romania. The control of infections and the identification of antibiotic resistant pathogens are critical in all clinical environments. Mobidiag offers a diverse range of products that are easy to use, have great diagnostic precision and are affordable. These products are very important for the general management of patients and hospitals and we see them offering a great opportunity for the future.”
Amnon Hezkaya CEO of Theranostica, continues "We are really excited to start this partnership between Theranostica and Mobidiag. Mobidiag with its Novodiag® solution has the potential to be transformational for Israeli clinical laboratory customers as an affordable, fast sample to result system, which can test multiple targets at once.”
- Ends -
Notes to editors
About Mobidiag Ltd
Mobidiag is a revenue generating, fast growing molecular diagnostics company with complementary platform technologies that can meet the differing diagnostic needs for customers in multiple healthcare settings. Initially designed for ease of use and adapatability for large scale manufacturing, Mobidiag’s Amplidiag® and Novodiag® platforms provide a combination of high quality and affordability, allowing for widespread applicability for both mass screening and highly specific syndromic testing in multiple indications. The Company’s highly versatile product offering enables the broad application of molecular diagnostics to address the global challenge of antimicrobial resistance and other unmet diagnostic needs. Mobidiag’s intial focus has been on gastrointestinal diseases and superbugs, through direct sales and distributors, and is rapidly building a leading position in European markets.
Mobidiag has more than 100 staff and is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com
About ALAB Ltd.
ALAB Ltd. based in Warsaw, Poland is a specialized company operating in the laboratory market in Poland and Ukraine. ALAB Ltd. is a member of ALAB GROUP including ALAB LABORATORIA – a key market player in routine and specialized diagnostics and ALAB PLUS – histopathology laboratory service. For 25 years ALAB Ltd. has been conducting commercial and service activities for public and private institutions. Its specialty is the comprehensive equipping of laboratory rooms in biotechnology, molecular biology, physico-chemical, microbiology and diagnostics.
About BIOgenetiX
BIOgenetiX is a distribution company for medical products in Romania. The company provides products and technical support for laboratories performing molecular biology diagnostic tests. BIOgenetiX addresses both state owned and private clinics, laboratories and hospitals. The company was established in 2009 and at the moment it is one of the most important Romanian companies in the field of medical products distribution. BIOgenetiX has a special program in the area of infections control and prevention. The company is focused on providing customers with more advanced technologies for molecular diagnostics and resistance genes identification.
Theranostica Ltd
Theranostica Ltd., established in 2010 is a leading Israeli distributor for innovative clinical diagnostics solutions from the United States, Europe and Asia. In the past nine years Theranostica has been succesful in bringing to the Israeli health system dozens of new technologies which helped to provide better medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191029005046/en/
Contact information
Johanna Sarapää, Marketing Communications
+358 10 2054 771
marketing@mobidiag.com
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Chris Welsh
T: +44 (0)203 709 5700
mobidiag@consilium-comms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom